IGF2 and neoplasm: Notably, we confirmed that the methylation defects more frequently affect the 11p15.5 DMRs (50% and 44% for H19/IGF2:IG-DMR and KCNQ10T1:TSS-DMR, respectively), but also demonstrated significant methylation changes (either loss or gain) at the other DMRs in the tumor tissue with respect to normal kidney, although in a lower number of cases (Figure 1B and Table S2).